首页 | 官方网站   微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   355814篇
  免费   27033篇
  国内免费   15646篇
医药卫生   398493篇
  2023年   3765篇
  2022年   9139篇
  2021年   12320篇
  2020年   8900篇
  2019年   8503篇
  2018年   9476篇
  2017年   8040篇
  2016年   7766篇
  2015年   11413篇
  2014年   14437篇
  2013年   14167篇
  2012年   20851篇
  2011年   22796篇
  2010年   13887篇
  2009年   11293篇
  2008年   15947篇
  2007年   16227篇
  2006年   15772篇
  2005年   15487篇
  2004年   11476篇
  2003年   10329篇
  2002年   9156篇
  2001年   12288篇
  2000年   12626篇
  1999年   11754篇
  1998年   5323篇
  1997年   4932篇
  1996年   3684篇
  1995年   3414篇
  1994年   2991篇
  1993年   2249篇
  1992年   5839篇
  1991年   5644篇
  1990年   5086篇
  1989年   4840篇
  1988年   4541篇
  1987年   4279篇
  1986年   3900篇
  1985年   3589篇
  1984年   2457篇
  1983年   2113篇
  1982年   1175篇
  1979年   2133篇
  1978年   1322篇
  1975年   1276篇
  1974年   1474篇
  1973年   1507篇
  1972年   1430篇
  1971年   1323篇
  1970年   1206篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
糖尿病患者腹部手术后消化道功能的观察   总被引:6,自引:0,他引:6  
目的了解糖尿病患者腹部手术后消化道功能恢复情况,为临床进行有针对性的护理提供依据.方法对72例糖尿病患者腹部手术后消化道功能恢复情况进行观察,并随机抽取70例非糖尿病腹部手术患者作对照.结果在肠鸣音恢复及肛门排气时间、进流质饮食后食欲状况、恶心呕吐、腹胀发生情况5个方面进行比较,两组消化道功能恢复差异明显(P均<0.01).结论糖尿病患者腹部手术后消化道功能恢复延迟,临床护理中应予重视.  相似文献   
92.
93.
94.
通过深入分析我国中医药科学性研究中所存在的问题,依据协同学理论,提出了中医药科学性的理论基础是协同学的观点。基于此,阐释了中医药科学性的协同学解释,这在一定意义上为中医药科学性的研究提供了新的视角和有益的启示。  相似文献   
95.
Serine hydroxymethyltransferase (SHMT) provides activated one-carbon units required for the biosynthesis of nucleotides, protein, and methyl group by converting serine and tetrahydrofolate to glycine and N(5),N(10)-methylenetetrahydrofolate. It is postulated that SHMT activity is associated with the development of methotrexate resistance and the in vivo activity of SHMT is regulated by the binding of N(5)-CHO-THF, the rescue agent in high-dose methotrexate chemotherapy. The aim of this study is to advance our understanding of the folate-mediated one-carbon metabolism in zebrafish by characterizing zebrafish mitochondrial SHMT. The cDNA encoding zebrafish mitochondrial SHMT was cloned, overexpressed in Escherichia coli, and purified with a three-step purification protocol. Similarities in structural, physical, and kinetic properties were revealed between the recombinant zebrafish mitochondrial SHMT and its mammalian orthologs. Surprisingly, leucovorin significantly inhibits the aldol cleavage of serine catalyzed by zebrafish cytosolic SHMT but inhibits to a lesser extent the reaction catalyzed by the mitochondrial isozyme. This is, to our knowledge, the first report on zebrafish mitochondrial folate enzyme as well as the differential inhibition of leucovorin on these two SHMT isoforms. Western blot analysis revealed tissue-specific distribution with the highest enrichment present in liver for both cytosolic and mitochondrial SHMTs. Intracellular localization was confirmed by confocal microscopy for both mitochondrial and cytosolic SHMTs. Unexpectedly, the cytosolic isoform was observed in both nucleus and cytosol. Together with the previous report on zebrafish cytosolic SHMT, we suggest that zSHMTs can be used in in vitro assays for folate-related investigation and antifolate drug discovery.  相似文献   
96.
目的:探讨腰椎形态结构变化对峡部裂性滑脱及小关节退变的作用和意义。方法:采用改良的“非种子区域分割方法”及非平行“最佳切割平面”等一系列新型计算机辅助设计(CAD)方法精确建立包括椎间盘高度、腰椎小关节角、椎间盘前凸角改变的L4~L5活动节段有限元模型;在2700N轴向压缩载荷条件下,分别对各有限元模型的峡部、小关节应力、小关节接触力以及椎间盘负载进行测试。结果:压缩载荷下,腰椎活动节段峡部、小关节等效应力及小关节接触力随椎间盘高度的减小而减小,随小关节角的增大而增加,随椎间盘前凸角的增加而减小。结论:椎间盘高度、腰椎小关节角、椎间盘前凸角等形态结构变化对腰椎节段有限元模型的峡部、小关节应力及小关节接触力有明显的影响。提示腰椎峡部应力性骨折及小关节退变的发生与椎间盘高度、腰椎小关节角、椎间盘前凸角等解剖形态因素有关。  相似文献   
97.
We previously reported that lymphatic mapping using isosulfan blue can be used to identify sentinel nodes (SNs). This study was undertaken to evaluate the feasibility of using the SN technique in treating early gastric cancer and to explore its usefulness for minimal invasive surgery. Twenty-three patients with early gastric cancer who underwent SN biopsy were retrospectively evaluated. Based on SN evaluation, individualized surgery was performed in five patients with T1N0M0 gastric cancer. When pathological examination of frozen sections revealed metastasis in SNs, we performed a standard D2 gastrectomy. Laparoscopic local resection was applied when the SN biopsy was negative. Our results showed that the success rate with SN biopsy in early gastric cancer was 100%, as were the accuracy, sensitivity, and specificity. All five patients with early gastric cancer had SNs negative for metastases both by frozen section and by postoperative pathology. Thus, all these patients underwent laparoscopic local resection without extended lymphadenectomy. We conclude that SN biopsy is a useful tool to individualize the operative procedure, and laparoscopic local resection can be safely performed using SN guidance in selected patients with early gastric cancer.  相似文献   
98.
Abstract   We evaluated the associations between glycemic therapies and prevalence of diabetic peripheral neuropathy (DPN) at baseline among participants in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial on medical and revascularization therapies for coronary artery disease (CAD) and on insulin-sensitizing vs. insulin-providing treatments for diabetes. A total of 2,368 patients with type 2 diabetes and CAD was evaluated. DPN was defined as clinical examination score >2 using the Michigan Neuropathy Screening Instrument (MNSI). DPN odds ratios across different groups of glycemic therapy were evaluated by multiple logistic regression adjusted for multiple covariates including age, sex, hemoglobin A1c (HbA1c), and diabetes duration. Fifty-one percent of BARI 2D subjects with valid baseline characteristics and MNSI scores had DPN. After adjusting for all variables, use of insulin was significantly associated with DPN (OR = 1.57, 95% CI: 1.15–2.13). Patients on sulfonylurea (SU) or combination of SU/metformin (Met)/thiazolidinediones (TZD) had marginally higher rates of DPN than the Met/TZD group. This cross-sectional study in a cohort of patients with type 2 diabetes and CAD showed association of insulin use with higher DPN prevalence, independent of disease duration, glycemic control, and other characteristics. The causality between a glycemic control strategy and DPN cannot be evaluated in this cross-sectional study, but continued assessment of DPN and randomized therapies in BARI 2D trial may provide further explanations on the development of DPN.  相似文献   
99.
背景:与小肠黏膜下层等材料相比,脱细胞血管具有天然管状结构,与输尿管形态结构相近,替代输尿管时仅需端端吻合即可,手术操作简单,血管外壁光滑,获取及制备方法简便等优点。 目的:拟应用同种颈动脉血管无细胞基质体外构建输尿管。 设计、时间及地点:观察性实验,于2006-09/2008-06在上海交通大学医学院附属新华医院动物实验中心完成。 材料:长风杂交白猪由上海松联实验动物公司提供。上海交通大学医学院实验动物中心提供的健康成年大鼠8只,用于血管无细胞基质的动物毒性实验。 方法:剥去猪颈动脉血管外膜,PBS冲洗若干遍,然后将血管置于pH 7.1 的PBS中4 ℃下振荡清洗,0.5%十二烷基硫酸钠振荡24 h,后使用双蒸水4 ℃下反复振荡洗涤1周,每日换双蒸水2次。对于解剖过程中肌肉残留相对稍多的血管,在双蒸水洗涤前以混合消化液37 ℃下振荡消化约2 h,再行双蒸水洗涤。制备的无细胞基质置于青、链霉素溶液中,4 ℃保存,完成脱细胞支架制备。 主要观察指标:光镜及电镜观察脱细胞后管壁无细胞基质片的主要成分。将同种异体来源内皮祖细胞培养增殖后植入血管无细胞基质,观察细胞生长情况,并进行血管无细胞基质动物毒性实验。拉力实验了解血管无细胞基质材料的收缩性能。 结果:颈动脉血管无细胞基质中已无细胞成分,无细胞基质主要由胶原成分组成。扫描电镜未见该材料表面存在细胞及细胞碎片,同时发现该无细胞基质存在孔隙样结构。体外同种异体来源的内皮祖细胞培养增殖后植入血管无细胞基质,细胞黏附于无细胞基质。血管无细胞基质按毒性分级属于无毒级。拉力实验说明该无细胞基质具有一定的韧性和牵张性。 结论:采用胰酶和十二烷基硫酸钠制备的颈动脉血管无细胞基质材料无细胞残留,具有一定的韧性和牵张性,种植于其中的种子细胞具备一定的生长能力。  相似文献   
100.
FDA’S Perspectives on Cardiovascular Devices   总被引:1,自引:0,他引:1  
The Food and Drug Administration (FDA) decision process for approving or clearing medical devices is often determined by a review of robust clinical data and extensive preclinical testing of the device. The mission statement for the Center for Devices and Radiological Health (CDRH) is to review the information provided by manufacturers so that it can promote and protect the health of the public by ensuring the safety and effectiveness of medical devices deemed appropriate for human use (Food, Drug & Cosmetic Act, §903(b)(1, 2(C)), December 31, 2004; accessed December 17, 2008 ). For high-risk devices, such as ventricular assist devices (VADs), mechanical heart valves, stents, cardiac resynchronization therapy (CRT) devices, pacemakers, and defibrillators, the determination is based on FDA’s review of extensive preclinical bench and animal testing followed by use of the device in a clinical trial in humans. These clinical trials allow the manufacturer to evaluate a device in the intended use population. FDA reviews the data from the clinical trial to determine if the device performed as predicted and the clinical benefits outweigh the risks. This article reviews the regulatory framework for different marketing applications related to cardiovascular devices and describes the process of obtaining approval to study a cardiovascular device in a U.S. clinical trial.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号